{"id":2937,"date":"2026-08-26T08:53:40","date_gmt":"2026-08-26T07:53:40","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/it\/?post_type=product&p=2937"},"modified":"2026-08-26T08:53:40","modified_gmt":"2026-08-26T07:53:40","slug":"buy-prostamax-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/it\/product\/buy-prostamax-in-switzerland\/","title":{"rendered":"Prostamax (20MG)"},"content":{"rendered":"

What Is Prostamax?<\/h2>\n

Prostamax is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (KEDP). It belongs to the Khavinson peptide series\u2014a family of short-chain peptides developed through research on tissue-specific bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. Researchers originally derived Prostamax from prostate tissue extracts and designed it as a synthetic analog for investigating prostate tissue function and gene regulation.<\/p>\n

As a tetrapeptide\u2014a peptide composed of exactly four amino acids\u2014Prostamax has attracted research interest for its proposed ability to interact with nuclear components including DNA and histones, thereby modulating gene expression through epigenetic mechanisms. Researchers classify Prostamax as a peptide bioregulator, meaning it may influence cellular processes through chromatin remodeling and transcriptional regulation rather than through classical receptor-mediated signaling. For those looking to buy Prostamax in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n

Prostamax Research Overview<\/h2>\n

Prostamax represents a well-characterized peptide bioregulator within the Khavinson research program. The peptide’s design\u2014a simple tetrapeptide sequence of lysine, glutamic acid, aspartic acid, and proline\u2014belies its proposed biological activity. Researchers have investigated Prostamax primarily for its tissue-specific effects on prostate-derived experimental systems, with implications for understanding gene expression regulation, chromatin structure, and age-related cellular changes.<\/p>\n

Research interest in Prostamax centers on its ability to modulate chromatin structure and gene expression in prostate tissue. Studies have demonstrated that Prostamax induces chromatin decondensation, reactivates genes repressed during aging, and influences cellular function in prostate-derived cell populations. Consequently, Prostamax has generated significant interest as a research tool for investigating tissue-specific gene regulation, epigenetic mechanisms, and age-related cellular changes.<\/p>\n

When researchers choose to buy Prostamax in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of prostate tissue bioregulation, chromatin remodeling, and gene expression at the molecular level.<\/p>\n

How Does Prostamax Work?<\/h2>\n

The proposed mechanism of Prostamax involves multiple interconnected pathways, including chromatin remodeling, epigenetic regulation, and tissue-specific gene modulation.<\/p>\n

Chromatin Remodeling and Deheterochromatinization<\/h3>\n

Prostamax’s primary mechanism involves selective relaxation of heterochromatin\u2014a process called deheterochromatinization. Research has shown that Prostamax induces chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin.<\/p>\n

In a 2004 study, researchers compared five Khavinson peptides (Vilon, Epithalon, Livagen, Prostamax, and Cortagen) in leukocytes from donors aged 75-88 years. All five peptides induced activation of ribosomal genes, decondensation of densely packed chromatin fibers, and release of genes suppressed by age-specific euchromatin region compression. Prostamax specifically induced decondensation of pericentromeric heterochromatin of chromosome 1.<\/p>\n

Epigenetic Regulation and Gene Expression<\/h3>\n

Prostamax is thought to regulate gene expression through epigenetic mechanisms mediated by direct interactions between the peptide and nuclear components including DNA and histones. Within the Khavinson model, peptides of this class are proposed to act at the chromatin level to modulate tissue-specific gene-expression patterns in experimental aging models.<\/p>\n

Furthermore, Prostamax appears to reverse age-related chromatin condensation selectively in prostate tissue, allowing normally silenced genes to activate. This mechanism supports the peptide’s tissue-specific effects on prostate-derived experimental systems.<\/p>\n

Tissue-Specific Gene Regulation<\/h3>\n

Prostamax is studied as a prostate-tissue-directed short-peptide probe, used to examine how a minimal defined peptide signal influences transcriptional, proteomic, and proliferation\/apoptosis endpoints in prostate-derived cell populations. In organotypic explant culture, KEDP has been reported to act tissue-specifically on prostate explants.<\/p>\n

Researchers who buy Prostamax in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of tissue-specific gene regulation and epigenetic modulation.<\/p>\n

Why Is Prostamax Studied?<\/h2>\n

Researchers study Prostamax primarily for its potential relevance to prostate tissue biology, gene expression regulation, and age-related cellular changes. The peptide’s ability to modulate chromatin structure and gene expression makes it a valuable tool for understanding the molecular basis of tissue-specific bioregulation and epigenetic mechanisms.<\/p>\n

The peptide’s connection to the Khavinson bioregulator program has made it a focus of prostate and epigenetic research. Preclinical studies have explored Prostamax’s effects on chromatin structure, gene expression, and cellular function in various experimental models, including prostate-derived cell populations, organotypic explant cultures, and aged rodent models.<\/p>\n

Moreover, researchers study Prostamax in the context of age-related cellular changes and tissue-specific gene regulation. As chromatin structure and gene expression patterns change with age, understanding mechanisms that support normal tissue function has become increasingly important. Prostamax represents one well-documented avenue of research inquiry in this area.<\/p>\n

Researchers who buy Prostamax in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on prostate tissue bioregulation, chromatin remodeling, epigenetic regulation, and age-related gene expression.<\/p>\n

Prostamax Research Areas<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nDescription<\/th>\n<\/tr>\n<\/thead>\n
Chromatin Remodeling<\/strong><\/td>\nInvestigating Prostamax’s ability to induce chromatin decondensation and deheterochromatinization<\/td>\n<\/tr>\n
Prostate Tissue Gene Expression<\/strong><\/td>\nStudying Prostamax’s effects on tissue-specific gene regulation in prostate-derived systems<\/td>\n<\/tr>\n
Epigenetic Regulation<\/strong><\/td>\nExamining Prostamax’s interaction with DNA, histones, and epigenetic mechanisms<\/td>\n<\/tr>\n
Age-Related Gene Reactivation<\/strong><\/td>\nExploring Prostamax’s potential to reactivate genes repressed during aging<\/td>\n<\/tr>\n
Ribosomal Gene Transcription<\/strong><\/td>\nInvestigating Prostamax’s effects on nucleolar organizer regions and rRNA gene activation<\/td>\n<\/tr>\n
Sister Chromatid Exchange<\/strong><\/td>\nStudying Prostamax’s influence on chromosomal stability and recombination<\/td>\n<\/tr>\n
Prostate Tissue Bioregulation<\/strong><\/td>\nPreclinical research into Prostamax’s tissue-specific effects on prostate explants<\/td>\n<\/tr>\n
Cellular Senescence<\/strong><\/td>\nExploring Prostamax’s potential relevance to age-related cellular changes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific Research on Prostamax<\/h2>\n

Researchers have conducted scientific studies on Prostamax in both in vitro and ex vivo settings, deriving evidence from cell cultures, organotypic explant cultures, and preclinical models. The peptide originates from the Khavinson research program, which has investigated tissue-specific peptide bioregulators for several decades.<\/p>\n

In Vitro Evidence<\/h3>\n

In vitro studies have demonstrated that Prostamax induces chromatin decondensation and activates ribosomal gene transcription in lymphocytes from older donors. A 2004 study reported that Prostamax incubation reactivates constitutive heterochromatin and rRNA-gene transcription in peripheral-blood lymphocytes of donors aged 60-79 years.<\/p>\n

Furthermore, research has shown that Prostamax increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging.<\/p>\n

Ex Vivo and Organotypic Studies<\/h3>\n

In organotypic explant culture, KEDP has been reported to act tissue-specifically on prostate explants. This tissue-specific activity supports the proposed role of Prostamax as a prostate-directed bioregulator. Research has also explored Prostamax’s effects on prostate tissue in aged rat models, demonstrating reduced inflammation and pathological remodeling.<\/p>\n

Human Research<\/h3>\n

Prostamax has limited human clinical evidence. The single PubMed-indexed canonical citation for Prostamax is the 2004 study by Khavinson and colleagues. The peptide has not been tested in human clinical trials, and no clinical trials are registered on ClinicalTrials.gov. All published research originates from the Khavinson research network, and independent replication remains a chief gap. Scientists who buy Prostamax in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\n

Prostamax Compared With Related Peptides<\/h2>\n\n\n\n\n\n\n\n\n\n
Peptide<\/th>\nRelationship to Prostamax<\/th>\nKey Differences<\/th>\n<\/tr>\n<\/thead>\n
Vesugen (KED)<\/strong><\/td>\nShares the N-terminal three residues of Prostamax<\/td>\nVesugen is a tripeptide (Lys-Glu-Asp) targeting vascular-endothelial tissue; Prostamax (KEDP) targets prostate tissue<\/td>\n<\/tr>\n
Pancragen (KEDW)<\/strong><\/td>\nShares the KED core sequence<\/td>\nPancragen has tryptophan at C-terminus targeting pancreatic tissue; Prostamax has proline targeting prostate tissue<\/td>\n<\/tr>\n
Livagen (KEDA)<\/strong><\/td>\nShares the KED core sequence<\/td>\nLivagen has alanine at C-terminus targeting liver tissue; Prostamax has proline<\/td>\n<\/tr>\n
Vilon (KE)<\/strong><\/td>\nShares the first two residues<\/td>\nVilon is a dipeptide (Lys-Glu) targeting thymus\/immune system; Prostamax is a tetrapeptide<\/td>\n<\/tr>\n
Epithalon (AEDG)<\/strong><\/td>\nSame Khavinson peptide series<\/td>\nEpithalon targets pineal gland and circadian rhythms; Prostamax targets prostate tissue<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Applications<\/h2>\n

Researchers utilize Prostamax in a variety of laboratory research applications, primarily in the fields of epigenetics, prostate biology, and tissue-specific gene regulation. Key research applications include:<\/p>\n